BioVie CEO Details Q2 2026 Start of 60-Patient Long COVID Phase II Trial
BioVie CEO outlined the upcoming Phase II long COVID trial design, confirming a Q2 2026 start with primary endpoints on symptom reduction and safety biomarker assessments. He detailed plans for a multi-center study across five U.S. sites with targeted enrollment of 60 patients.
1. CEO Outlines Long COVID Trial Details
BioVie’s CEO provided an overview of the planned Phase II study, confirming a Q2 2026 launch with 60 patients enrolled across five U.S. centers. He highlighted the trial’s focus on reducing fatigue and measuring safety through immune and inflammatory biomarkers, but did not disclose any interim efficacy data.
Related News
NEWP
Bolivia Overhauls Regulations as New Pacific Metals Poised for $700 Million Mining Boost
NEWP•
GS
Oil Prices Rebound to $99–$106 After Trump Iran Deal Comments, Inventories Drop
GS•
IPW
iPower Cuts Q3 Costs 66%, Narrows Loss to $0.3M, Secures $2.6M Sublease
IPW•
NVDA
Nvidia Targets $200 Billion Agentic AI Market with Vera CPU Launch
NVDA•
AMZN
AWS Faces Challenge as Nvidia Forecasts $91B Q3 Sales, Musk Eyes 2028 Space Data Centers
AMZN•
Sources
F